Navigation Links
Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
Date:9/28/2011

MISSISSAUGA, Ontario, Sept. 28, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that its wholly owned subsidiary, Valeant International (Barbados) SRL, has received notice that the New Drug Submission for colesevelam hydrochloride (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, has been approved by the Canadian regulatory authority Health Canada.

"Cardiovascular Disease is the cause of one in three deaths in Canada and managing Hypercholesterolemia, by lowering LDL-C (bad) cholesterol has been well-recognized as the primary goal of treatment, in managing the risk of cardiovascular disease," said Dr. Jean Davignon, Director of the Hyperlipidemia and Atherosclerosis Research Group of the Institut de recherches cliniques de Montreal (IRCM).  "The Canadian Cardiovascular Society has recently adopted more aggressive LDL-C targets; however, a substantial proportion of patients treated with a statin class of medications either do not attain their LDL-C targets or are unable to comply with their treatment due to adverse effects.  The launch of new drugs, such as colesevelam, that can be added to statins will be an important component of the pharmacological armamentarium to get many of these more difficult to manage patients to their recommended, much more aggressive lower LDL-C targets."

"Colesevelam is a strong addition to our Canadian franchise," said J. Michael Pearson, Valeant's chairman and chief executive officer. "Bile acid sequestration is a time-tested and well-established method that has been used literally for generations to lower both total and LDL-cholesterol. Clinical trials have shown reduced cardiovascular events with the use of bile acid sequestrants, either as monotherapy or in combination with other agents. Compared with conventional bile acid sequestrants, colesevelam has
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
2. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
3. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
4. Valeant Pharmaceuticals to Present at Industry Conferences
5. Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
6. Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid
7. Valeant Pharmaceuticals Completes Acquisition of Sanitas Group
8. Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeants Board of Directors
9. Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results
10. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
11. Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta™ in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/19/2014)... robust development with the growth pace keeping at 20%-30% in ... the size of China separating membrane ... to 16.3%. It is projected that China ... around 20% in the upcoming years and that the figure ... An integrated membrane industrial system has taken shape in ...
(Date:12/17/2014)... , Alemania, December 17, 2014 ... año anterior, con un alto nivel de gasto en ... año fiscal 2013/14 (finalizado el 30 de septiembre de ... ciento a 4.287 millones de euros (año anterior: 4.190 ... la moneda desfavorables. Las ganancias (EBIT) crecieron un 14 ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS confirma su posición en un entorno difícil 2
(Date:12/19/2014)... From November 24, 2014, Siddhi Yoga ... 2014 in its Goa retreat . This is the ... winters, from November to March, Siddhi Yoga will organize four ... Goa. The Goa training sessions will conclude in March 2015. ... training, the 10th intake is also a 200 YTT ...
(Date:12/19/2014)... December 19, 2014 Consilium Staffing, ... the AMSUS Society for Federal Health Professionals annual ... tenens industry to military and federal healthcare providers. ... National Veterans Small Business Engagement (NVSBE) conference last ... to be a vital solution in addressing our ...
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- The tragic death from "rat-bite ... carried by the pet rodents, according to a report from ... fever is a rare but potentially fatal illness that should ... and when a history of rodent exposure is reported," said ... Epidemic Intelligence Service. The case outlined in the report ...
(Date:12/19/2014)... analogue eye drops -- a common form of glaucoma ... in patients with the eye disease, a new study ... the Moorfields Eye Hospital and UCL Institute of Ophthalmology ... newly diagnosed with open-angle glaucoma -- the most common ... causes of blindness. About 45 million people worldwide ...
(Date:12/17/2014)... Marlborough, Mass. (PRWEB) December 17, 2014 ... College of Osteopathic Medicine (ACOM), which welcomed its ... Virtual Desktop Infrastructure (VDI) to seamlessly support bring ... learning – and teaching – experience. The solution, ... Citrix NetScaler , Dell server and storage ...
Breaking Medicine News(10 mins):Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... comes to mating, male chimpanzees have the opposite taste when ... species, human beings, //according to a study published Tuesday. ... older females and turn up their nose at younger ones. ... on studies of a group of Kanyawara chimpanzees in Uganda's ...
... a mother of two children died of breast cancer due to ... //Dr.John Philip was not qualified to read mammograms according to the ... Jackson. ,The woman who is identified as Mrs. A, ... her that she was normal. When she went for a second ...
... Centre at Canada's University //of British Columbia conducted a ... Alzheimer’s disease. , ,During the study, the researchers ... low-oxygen levels for about 16 hours a day, which ... normal levels of oxygen. ,After a month ...
... that sex does not increase the chances of heart attack, ... to movie mythology. //The study reported that ‘while sex causes ... could lift the likelihood 20-folds’. ,The review by ... analyse triggers for heart attacks, including sexual activity, cocaine use, ...
... US government has awarded three more contracts to buy and ... 2.7 million people, at a cost of $199.45 million. ... (HHS) the contracts are for a total of 5.3 million ... to GlaxoSmithKline (GSK) for 800,000 doses, $40.95 million to Novartis ...
... who suffer from allergy to grass pollen will now ... introduced, tablet based //vaccine named Grazax? is being marketed ... treatment. ,Allergy from grass pollen prominently disrupts quality ... social interaction severely .Statistics reveal that over 45 million ...
Cached Medicine News:Health News:US Orders More H5N1 vaccine 2
... RX600 is a versatile, fully powered orthopaedic ... built-in traction facilities, a powered centre break ... extremely versatile too. ,<br.,In fact the RX600 ... as it is for traction procedures. The ...
... For complete orthopedic trauma procedures. ... system, the orthopedic trauma table top ... for easy patient positioning and provides ... key trauma procedures: hip pinnings; femur, ...
... The EXOGEN 2000+ device provides a ... nonunion or the acceleration of fresh ... home for 20 minutes daily, or ... your physician determines your fracture to ...
... cannulated interference screws have a ... screw divergence. Screws are available ... lengths. Screws are supplied sterile, ... and 9mm dia. (screws are ...
Medicine Products: